Peptide Injections for Weight Loss: What's in the Vial (2026)

Search "peptide injections for weight loss" and you will be shown three completely different products under one label: an FDA-approved prescription medicine, a compounded copy of that medicine prepared by a pharmacy, and an unregulated vial mailed from a website with "for research use only" on the box. They can contain nominally the same molecule. They are not the same purchase, and the differences are not paperwork — laboratory analyses have measured what actually arrives at the door.

The short version: the injectable weight-loss peptides with real evidence are the incretin drugs, and the evidence attaches to the approved product tested in the trial, not to the molecule in the abstract. How you obtain it determines whether any of that evidence transfers. That is the argument of this page.

The three tiers, and why the distinction is the whole story

Tier one: FDA-approved incretin drugs. Semaglutide and tirzepatide are approved, manufactured under pharmaceutical quality systems, and carry the trial data everyone quotes. In STEP 1, 1,961 adults randomised to once-weekly semaglutide 2.4 mg or placebo for 68 weeks saw mean body-weight change of −14.9% versus −2.4%¹. In SURMOUNT-1, 2,539 adults on tirzepatide reached −15.0%, −19.5% and −20.9% at 5, 10 and 15 mg against −3.1% for placebo². The investigational triple agonist retatrutide reached −24.2% at 48 weeks in phase 2, and remains unapproved³.

Tier two: compounded versions. A licensed compounding pharmacy prepares the drug against a prescription. There is a real prescriber and a licensed pharmacy in the chain, which matters. But state it plainly, because a lot of marketing does not: compounded semaglutide and tirzepatide are not FDA-approved products. They have not been through the agency's review of safety, efficacy or manufacturing for that specific preparation. The trial results above were generated with the approved product, and they do not automatically carry over to a different preparation at a different concentration from a different facility.

Tier three: "research use only" vials sold online without a prescription. No prescriber, no pharmacy, no dispensing standard, and no obligation to make what the label claims. This is where the measured data gets ugly.

What testing actually found inside grey-market vials

This is not a hypothetical risk, and it is worth going through the numbers rather than gesturing at "quality concerns."

A 2024 market-surveillance study published in the Journal of Medical Internet Research did what almost nobody does: it bought the product. Researchers screened 1,080 search-result links, identified 317 belonging to online pharmacies of which 183 were illegal, and made test purchases from six illegal online pharmacies offering semaglutide without prescription at the lowest prices. Three prefilled-pen orders never arrived at all — straightforward e-commerce fraud. Three vials were delivered and analysed⁴.

The results deserve to be read slowly:

• •Semaglutide content exceeded the labelled amount by 28.56% to 38.69%. Not less than promised — more, which is its own dosing hazard.
• •Measured semaglutide purity ranged from 7.7% to 14.37%, against the 99% claimed on the labels⁴.
• •Endotoxin was detected in all samples, at 2.1645 to 8.9511 EU/mg, in material intended for injection⁴.

Hold those two purity figures side by side. If a vial is 7.7% to 14.37% pure and simultaneously over-labelled on content, the great majority of what is being injected is something other than the drug, and nobody in the chain can say what.

That pattern is not confined to semaglutide. A systematic impurity-profiling study of the ten most frequently encountered falsified peptide drugs on the Belgian market, purchased from three suspected illegal internet pharmacies, found high variation in drug quantity per unit and purity ranging between 5% and 75% for cysteine-containing peptides — plus contamination with arsenic and lead, with multiple samples reaching concentrations up to ten times the international toxicity limit for parenteral drugs⁵. Injectable products, heavy metals, ten times the limit.

This is the concrete answer to "is a cheap vial really that different." It is measurably different, and the measurements have been published.

The dose arithmetic that gives false comfort

A specific failure mode is worth naming because it is so common. Someone reconstitutes a grey-market vial, works the concentration carefully, and concludes the dosing is precise.

The arithmetic is not the weak link. Converting a labelled mass and a volume of diluent into micrograms per syringe unit is exact, and our semaglutide reconstitution calculator, tirzepatide reconstitution calculator and general peptide calculator will do it to the decimal. The weak link is the input. Every one of those calculations starts from the number printed on the label, and the analyses above found that number wrong by 28–39% in one direction while purity sat below 15%⁴. A precise answer computed from a false input is not precision; it is confidence in the wrong place. The technique itself is covered in how to reconstitute peptides, and the diluent has its own rules in our bacteriostatic water guide.

The side-effect profile that comes with the real drug

Even at tier one, these injections are not consequence-free, and the athletic corners of the internet tend to underplay it.

Gastrointestinal adverse events are the dominant tolerability issue. In STEP 1, nausea and diarrhoea were the most common adverse events, and 4.5% of the semaglutide group discontinued treatment for gastrointestinal events versus 0.8% on placebo¹. A state-of-the-art safety review notes that beyond the familiar nausea, vomiting, diarrhoea and constipation of dose escalation, accumulating evidence has identified further gastrointestinal complications including cholelithiasis, cholecystitis, gastroparesis and bowel obstruction⁶. A cross-sectional analysis of a large research cohort likewise found an association between GLP-1 receptor agonist use and gastrointestinal adverse events⁷ — and it is worth being precise about what a cross-sectional association can and cannot establish, which is prevalence in a population rather than causation in an individual.

None of this makes these drugs bad medicines. It makes them medicines, which is exactly the frame the "peptide injection" marketing removes.

What about the non-incretin injectables?

The other injectables marketed for weight loss are a different evidentiary category altogether, and mostly a much weaker one.

The growth-hormone fragments — AOD-9604 and HGH fragment 176-191 — are the compounds sold most explicitly as fat-loss injections, and their human programme did not deliver on the promise the mechanism implied; we lay that out in the AOD-9604 evidence review and the HGH fragment 176-191 review. Tesamorelin is a genuine approved drug with randomised visceral-fat reduction, but in a specific clinical population for a specific fat depot, which we cover in tesamorelin for athletes. The GH secretagogues are sold on a lipolysis rationale that has never converted into demonstrated fat loss in healthy training people — see peptides for fat loss. And if the underlying goal is losing fat without losing muscle, the body-composition evidence is its own subject, which we work through in peptides for weight loss and muscle gain.

For anyone drug-tested, most of this category is banned in tested sport, year-round, and a prescription does not change that. Our prohibited-substance checker gives a per-compound answer rather than a rule you have to apply yourself.

The decision this page is really about

If you have concluded that an incretin drug is appropriate for you, the meaningful choice is not which molecule — it is which tier you buy from, because the evidence and the risk both attach to the tier rather than the name.

The approved product carries the trial data and a manufacturing chain. A compounded prescription carries a licensed clinician and a licensed pharmacy, with the honest caveat that it is not an FDA-approved product and the trial results were not generated with it. The unregulated vial carries a published record of sub-15% purity, over-labelled content and endotoxin in every sample tested⁴, and, in the wider falsified-peptide literature, heavy metals above parenteral toxicity limits⁵.

Those are not three prices for one product. They are three different products, and only one of them was in the trial.